{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:32:24Z","timestamp":1793068344233,"version":"4.5.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Alopecia associated with lupus erythematosus is broadly classified into reversible nonscarring alopecia seen in the acute phase, such as worsening of systemic lupus erythematosus (SLE) and cicatricial alopecia seen in chronic cutaneous lupus erythematosus represented by discoid lupus erythematosus (DLE). In DLE-induced alopecia, early therapeutic intervention before developing scarring alopecia is important, but the condition is often resistant to conventional treatment. Anifrolumab (ANI), a novel therapeutic agent for SLE that inhibits Type I interferon activity, has been shown to be effective against acute skin lesions, including alopecia, in patients with SLE. However, there are very few reports on the effect of ANI on alopecia due to DLE. We report on a 27-year-old Japanese woman with SLE whose alopecia due to chronic DLE was refractory to topical therapy and systemic therapy with oral glucocorticoid, multiple immunosuppressants, and belimumab for \u223c8\u2009years after onset and whose alopecia improved with ANI. ANI can be considered to be an effective treatment option in lupus patients presenting with alopecia due to DLE, even in the chronic refractory stage.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae018","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T03:57:22Z","timestamp":1712375842000},"page":"267-271","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-1535","authenticated-orcid":false,"given":"Naoto","family":"Azuma","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine , Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Natsuaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hyogo Medical University School of Medicine , Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine , Nishinomiya, Hyogo, Japan"},{"name":"Hashimoto Rheumatology Clinic , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine , Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine , Nishinomiya, Hyogo, Japan"},{"name":"Division of Rheumatology and Allergy, Osaka General Medical Center , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine , Nishinomiya, Hyogo, Japan"},{"name":"Department of Rheumatology, Hyogo Prefectural Nishinomiya Hospital , Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Jinnin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University Graduate School of Medicine , Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine , Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"2024083009010582300_R1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.det.2012.08.008","article-title":"Autoimmune disease and hair loss","volume":"31","author":"Moghadam-Kia","year":"2013","journal-title":"Dermatol Clin"},{"key":"2024083009010582300_R2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2024083009010582300_R3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2022.5242","article-title":"Treatment with anifrolumab for discoid lupus erythematosus","volume":"159","author":"Trentin","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2024083009010582300_R4","article-title":"Alopecia secondary to severe discoid lupus responding to anifrolumab","volume":"9","author":"Han","year":"2023","journal-title":"Int J Womens Dermatol"},{"key":"2024083009010582300_R5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2023.04.024","article-title":"Successful treatment of severe chronic cutaneous lupus with anifrolumab: a series of 6 cases","volume":"37","author":"Kowalski","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2024083009010582300_R6","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024083009010582300_R7","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"2024083009010582300_R8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.11.022","article-title":"The influence of interferon on healthy and diseased skin","volume":"132","author":"Hile","year":"2020","journal-title":"Cytokine"},{"key":"2024083009010582300_R9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/mr\/road015","article-title":"Relationships between type 1 IFN signatures and clinical features of the newly-onset lupus patients in Japan","volume":"34","author":"Shirahama","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2024083009010582300_R10","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03010-0","article-title":"Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis","volume":"25","author":"Miyachi","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2024083009010582300_R11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlated with the cutaneous lupus area and severity index score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol"},{"key":"2024083009010582300_R12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jamadermatol.2023.0175","article-title":"Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus","volume":"159","author":"Shaw","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2024083009010582300_R13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1346-8138.2011.01416.x","article-title":"Primary cicatricial alopecia: recent advances in understanding and management","volume":"39","author":"Ohyama","year":"2012","journal-title":"J Dermatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae018\/57505004\/rxae018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/2\/267\/58970195\/rxae018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/2\/267\/58970195\/rxae018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T09:27:04Z","timestamp":1725010024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/8\/2\/267\/7643531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae018","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,4,10]]}}}